Margaret Okomo-Adhiambo

Suggest Changes
Learn More
The clinical use of the neuraminidase inhibitor (NAI) oseltamivir is associated with the emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations. The influenza(More)